Podcasts about Lung cancer

What does it really take to raise money for a cause that many people misunderstand?  In this conversation, Natalie Reilly-Finch, the Vice President of Growth at the Lung Cancer Research Foundation (LCRF), shares the real challenges behind fundraising for lung cancer research and the responsibility that comes with it. She has been working in fundraising since she was 18 and now leads LCRF's growth efforts. She explains that LCRF is the largest private funder of lung cancer research, helping to close the gap left by limited federal funding. Natalie is deeply committed to changing public perception and supporting everyone affected by lung cancer. During the discussion, Natalie addresses the stigma surrounding lung cancer, especially the belief that it only affects smokers or that it is not a woman's disease. She explains how fundraisers must create urgency without making people feel blamed or judged. She also talks about understanding donor motivations, listening carefully, and using data to build strong connections. Through personal stories and practical advice, Natalie highlights the importance of empathy and flexibility while continuing the fight for a cure. In this episode, you will be able to:  Understand the stigma surrounding lung cancer and how it impacts fundraising efforts. Recognize the importance of balancing urgency with hope in cause-based messaging. Learn how to communicate about sensitive issues without blaming or shaming affected communities. Discover how donor segmentation and data can improve fundraising effectiveness. Gain insights into identifying and aligning with a donor's deeper motivations. Get all the resources from today's episode here.  Support for this show is brought to you by Practivated. Practivated delivers AI-powered donor conversation simulations that let fundraisers practice in a private, judgment‑free space—building confidence, refining messaging, and improving outcomes before the real conversation even begins. Developed by fundraising experts with real‑time coaching at its core, it's the smart way to walk into every donor interaction calm, prepared, and ready to connect. Learn more at practivated.com. Connect with me:  Instagram: https://www.instagram.com/_malloryerickson/ Facebook: https://www.facebook.com/whatthefundraising YouTube: https://www.youtube.com/@malloryerickson7946 LinkedIn: https://www.linkedin.com/mallory-erickson-bressler/ Website: malloryerickson.com/podcast Loved this episode? Leave us a review and rating here: https://podcasts.apple.com/us/podcast/what-the-fundraising/id1575421652 If you haven't already, please visit our new What the Fundraising community forum. Check it out and join the conversation at this link. If you're looking to raise more from the right funders, then you'll want to check out my Power Partners Formula, a step-by-step approach to identifying the optimal partners for your organization. This free masterclass offers a great starting point

Kate met Shira Boehler when they were both parents at the same preschool, and the two quickly became great friends. Late last year, after a preventative screening, Shira was unexpectedly diagnosed with lung cancer, despite having no symptoms and never smoking. Early detection allowed her to undergo surgery and successfully treat the cancer. Now, Shira is determined to make lung cancer screenings accessible to everyone, especially women. She is the author of One Scan Saved My Life and the creator of the cancerdoesntcare foundation, which supports lung screening access and research. Reality Life with Kate Casey What to Watch List: https://katecasey.substack.com Patreon: http://www.patreon.com/katecasey Twitter: https://twitter.com/katecasey Instagram: http://www.instagram.com/katecaseyca Tik Tok: https://www.tiktok.com/@itskatecasey?lang=en Facebook Group: https://www.facebook.com/groups/113157919338245 Amazon List: https://www.amazon.com/shop/katecasey Like it to Know It: https://www.shopltk.com/explore/katecaseySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Advanced practice providers discuss biomarker testing in patients with lung cancer. Listen in to learn from Beth Sandy, MSN, CRNP,FAPO, and Denise Rouse, MS, PA-C, about key biomarker testing in patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients with lung cancer. Presenters: Beth Sandy, MSN, CRNP, FAPO  Thoracic Oncology Nurse Practitioner Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Denise Rouse, MS, PA-C  Physician Assistant Thoracic Medical Oncology Department of Medicine, Section of Hematology/Oncology The University of Chicago Medicine & Biological Sciences Chicago, Illinois Link to full program: https://bit.ly/4rt1OCl Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

As part of IASLC's ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with two expert cardiothoracic surgeons, Dr. Ben Li, Professor from The First Affiliated Hospital of Guangzhou Medical University and, and Dr. Calvin Ng, Professor from the Chinese University of Hong Kong. The discussion: reviews surgical management of early-stage NSCLC, including VATS, and lobar versus sublobar resection; and explores novel technologies including endobronchial therapy and tubeless anesthesia. Host: Molly Li, MD Clinical Assistant Professor Department of Clinical Oncology, CUHK, Hong Kong Guests: Shuben Li, MD, PhD Professor, Department of Thoracic Surgery National Center for Respiratory Medicine The First Affiliated Hospital of Guangzhou Medical University Calvin S.H. Ng, BSc MBBS, MD Environmental Foundation Professor of Thoracic Surgery Department of Surgery The Chinese University of Hong Kong (CUHK)

In this episode, Dr. Paul Wheatley-Price chats with Dr. Lisa Hicks, a hematologist-oncologist at St. Michael's Hospital, who specializes in caring for medically and socially complex people with blood cancer. They talk about the unique neighbourhood that she serves in downtown Toronto, what are the social determinants of health, how various aspects of poverty and societal inequity might impact those with a lung cancer (or other cancer) diagnosis.

In this episode of Conversations in Lung Cancer Research, host A/Prof Mel Moore interviews Dr. Megan Sanders, the Chief Executive Officer of TOGA. They discuss Megan's journey from working in vaccine formulation to earning a PhD in immunology, working in clinical trials, and eventually leading TOGA. They explore the challenges and achievements of TOGA, the importance of multidisciplinary engagement in lung cancer treatment, and the organisation's strategic plan for strengthening research and membership engagement. The conversation touches on the potential of clinical quality registries to improve patient care and highlights the ongoing effort to address the gaps in funding and equitable care for lung cancer patients.(00:00) Introduction and Acknowledgements(00:36) Meet Dr. Megan Sanders: From Science to Leadership(01:21) Journey from Academia to Clinical Trials(05:27) Challenges and Rewards in Clinical Trials(09:24) TOGA's Achievements and Multidisciplinary Approach(26:39) Future Directions and Strategic Plans(36:55) Conclusion and Final Thoughts Links: Dr Megan Sanders https://www.linkedin.com/in/megan-sanders-20130156/TOGA Strategic Plan: https://thoraciconcology.org.au/news/toga/toga-launches-new-strategic-plan-2025-2028-to-advance-thoracic-cancer-research-in-australasia/TOGA ASM 2026:https://thoraciconcology.org.au/events/toga-annual-scientific-meeting-2026/

Please visit answersincme.com/RCG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Raymond Osarogiagbon, MD, MBBS, FACP, FASCO; and Michael Gieske, MD. In this activity, experts in lung cancer discuss practical strategies for lung cancer screening. Upon completion of this activity, participants should be better able to: Recognize barriers to achieving lung cancer screening for eligible patients; Identify patients at high risk of lung cancer who are eligible for screening; and Outline practical, patient-centered strategies to appropriately integrate lung cancer screening into routine practice.

Send us a textMorning Prayer - God - Lung Cancer - Unborn Children - Work God Has For UsThank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

PLEASE support lung cancer awareness https://www.thewhiteribbonproject.org/

This episode of Lung Cancer Considered, hosted by Dr. Narjust Florez, examines the challenges of delivering lung cancer care in areas affected by war and displacement with guests Dr. Julie Gralow and Dr. Rafal Dziadziuszko. The discussion addresses disrupted diagnosis and treatment, heightened inequities, and unique environmental exposures that may increase lung cancer risk in conflict settings. The episode also highlights emerging opportunities through global collaboration, adaptable care models, and shared responsibility across the oncology community. Guests: Dr. Julie Gralow, Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO). She is also the founder of the Women's Empowerment Cancer Advocacy Network (WE CAN) and an expert in global oncology. Rafał Dziadziuszko, M.D., Ph.D., professor of medicine, Head, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical University of Gdańsk in Poland

Guy's and St Thomas' starts trialling AI plus robot-guided tools to speed up lung cancer diagnosis — less waiting, more answers. Up the country, the MoD pushes forward “wingman drones” designed to fly alongside Apache helicopters, because 2026 is really leaning into the sci-fi timeline. Then we swerve hard into gaming: Terraria drops its massive Bigger and Boulder update, Steam owner Valve gets pulled into a huge UK lawsuit over pricing and commissions, and Sony adds PS5 read receipts — so now your mates can see you're ignoring them. More at standard.co.uk — and don't forget to follow for your next weekday hit! Hosted on Acast. See acast.com/privacy for more information.

Early detection and advanced surgical care are changing the outlook for lung cancer. Discover how robotic technology is helping doctors treat lung cancer earlier, safer and with a faster recovery. Featuring thoracic surgeon Gavin Henry, MD, FACS.  For more information about Dr. HenryFor more information about Thoracic Surgery at the Tate Cancer CenterFor other locations in Maryland

Transforming your health is more fun with friends! Join Chef AJ's Exclusive Plant-Based Community. Become part of the inner circle and start simplifying plant-based living - with easy recipes and expert health guidance. Find out more by visiting: https://community.chefaj.com/ For a list "The Top 10 Things Having Cancer Has Taught Me" please email help@ChefAJ.com Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. To book a consultation with Matt: https://form.jotform.com/241997228318164 Matthew Lederman, MD, is a board-certified Internal Medicine Physician and a pioneering thought leader in holistic health. Renowned for his innovative integration of plant-based nutrition, Nonviolent Communication (NVC), trauma-informed care, and lifestyle medicine, Dr. Lederman's work highlights the profound interconnectedness of physical, emotional, and relational well-being. As a certified Nonviolent Communication Trainer through the Center for Nonviolent Communication (CNVC), Dr. Lederman combines Polyvagal Theory, Somatic Awareness Principles, and Pain Reprocessing to empower individuals to heal from within. His approach helps people address the root causes of chronic health challenges, fostering emotional resilience and cultivating meaningful connections. Dr. Lederman is the co-host of the webe Parents podcast, a platform dedicated to equipping parents with tools and insights to foster emotional connection, resilience, and well-being in their families. His latest book, Wellness to Wonderful, weaves together medical science, psychology, spirituality, and life wisdom to guide individuals toward lasting health, vibrancy, peace, and joy. He is also the co-founder of Kinectin, a platform designed to help individuals build deeper, more fulfilling relationships through AI-driven coaching and personalized assessments. Email (questions & requests): Support@ConnectionDocs.com Website: https://www.connectiondocs.com/ Free Resources (includes Feelings & Needs Sheet for children AND Role-Play Video “Talking to Your Child About ‘Too Much' Device Time”) : https://www.connectiondocs.com/resources Substack (Weekly Articles on Connection): https://substack.com/@connectiondocs Breath & Body Regulation Training Tool: https://webekalm.com/ webe Pärents Podcast https://webekalm.com/pages/webeparents AI Connection Coach:https://app.kinectin.com/signup Main Book WELLNESS TO WONDERFUL: 9 Pillars for Living Healthier, Longer, and with Greater Joy: https://www.amazon.com/dp/B0C2S1JGZK?ref=cm_sw_r_ffobk_cso_sms_apin_dp_K6HM5P02NNK5WAMRGE87&ref_=cm_sw_r_ffobk_cso_sms_apin_dp_K6HM5P02NNK5WAMRGE87&social_share=cm_sw_r_ffobk_cso_sms_apin_dp_K6HM5P02NNK5WAMRGE87&starsLeft=1&skipTwisterOG=1&bestFormat=true Children's E-Books (Supporting Children Bringing More Connection Into Their Lives): Healing Shame and Connecting to Self-Worth and Intrinsic Value: https://webekalm.com/products/lily-and-her-beautiful-flower Being Honest with Care https://webekalm.com/products/ella-and-the-two-gifts-ebook Supporting Children During Emergencies (fires, earthquakes, etc):'https://webekalm.com/products/brave-hearts-facing-the-fire-ebook Social Media: Instagram: https://www.instagram.com/TheConnectionDocs Substack Newsletter: https://connectionDocs.substack.com Facebook: https://www.facebook.com/connectionDocs X: https://x.com/connectionDocs

In our second episode of the "Perspectives" series, Dr. Paul Wheatley-Price chats with two guests, both with a depth of experience in ROS1+ lung cancer, a rare subtype of non-small cell lung cancer (NSCLC) which represents only about 1-2% of all lung cancer cases in Canada. Rev. Richard Reimer from Edmonton shares his story being diagnosed in 2009 with stage 4 lung cancer that was later identified as ROS1, and how he's been navigating life ever since. Dr. Geoffrey Liu is a Medical Oncologist at the Princess Margaret Cancer Center in Toronto and provides his clinical expertise on what is ROS1, how common is it, how does it get tested, and what the current treatment options are for those diagnosed with this rare subtype of lung cancer. This episode is dedicated to Richard's late beloved wife, Dana Rayment ❤️

This episode reviews the IASLC 2025 Hot Topic in Basic and Translational Science Conference, which focused on unraveling precancer and early-stage lung cancer, a theme that really captures where the field is heading. Instead of reacting to advanced disease. Guests: Dr. Triparna Sen, a professor of Internal Medicine at The Ohio State University and the director of the Lung Cancer Preclinical Therapeutics Platform at the OSUCCC – James. She also serves as the associate director of research for the Division of Medical Oncology. Her research focuses on understanding and therapeutically targeting mechanisms of therapy resistance and lineage plasticity in lung cancer, with a primary emphasis on small cell lung cancer (SCLC) and biologically aggressive subsets of non-small cell lung cancer. Dr. Aaron Tan is a physician-scientist whose work bridges early detection, translational biology, and clinical relevance in lung cancer. Dr. Tan is a Medical Oncologist at the National Cancer Centre Singapore (NCCS), where he is involved in early drug development, genomics with a focus on EGFR mutated lung cancer, and clinical implementation of liquid biopsy including for advanced lung cancer and MRD in early-stage lung cancer.

As part of IASLC's Lung Cancer Considered World Language Series, guest host Dr. Maria Cecilia Mathias leads a discussion in Portuguese about the junior faculty perspective with Dr. Maria Thereza Starling and Dr. Paula Duarte.

HOST: Hildy Grossman CO-HOST, Jordan Rich Guests: Justin Gainor, MD, Director of Targeted Immunotherapy at the Massachusetts General Hospital and David Barbie, MD, Director of the Barbie Lab at Dana Farber Cancer Institute Targeting Innate Immunity in Cancer Lung cancer has long been one of the most complex and difficult cancers to treat. But what if we could outsmart it—not just with surgery, chemotherapy, or radiation, but by training the immune system itself? This episode explores a revolutionary question: Could a vaccine change the future of lung cancer? To shed light on answers to this question are Dr. Justin Gainor, whose interest is in vaccine development, and Dr. David Barbie, who returns to Backstage @ Upstage to explain how the immune system responds to cancer. Our renowned guests describe the challenges of creating a therapeutic vaccine and why a preventative vaccine is less likely to succeed. They detail how the immune system's delicate operations need to be understood to successfully develop a vaccine to treat lung cancer. Moreover, you'll want to hear about the groundbreaking promise of “personalized vaccines” tailored to an individual's unique genomic markers, and how these cutting-edge vaccines will change the future of oncology forever. 

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Michael Lanuti, Director of Thoracic Oncology in the Division of Thoracic Surgery at Massachusetts General Hospital and an Associate Professor at Harvard Medical School, and thoracic surgeon and CTSNet Senior Editor Leanne Ashrafian about Dr. Lanuti's thoughts on the JCOG0802 trial and how he believes the wrong parameters were measured. Chapters 00:00 Intro 01:52 JANS 1, ESTS Guidelines 05:09 JANS 2, Resident-Led Operating 06:57 JANS 3, Fasting Impact on Pulm Aspiration 10:02 JANS 4, What Does a Dr Look Like 12:00 Video 1, Robotic Resection & Reconstruction 13:31 Video 2, Neonatal Off-Pump Shunt DORV 15:11 Video 3, Min Inv Bi-IMA OPCAB 16:12 Dr. Lanuti, JCOG0802 Results 44:58 Upcoming Events 45:38 Instructional Video Competition 45:49 Career Center They discussed local recurrence rates, pulmonary function, and the subtypes of adenocarcinoma. Additionally, they explored how to apply these results to future patients, central and peripheral lesions, and other randomized trials. They also covered the five-year results of the JCOG0802 trial and future studies and the implications for future studies, focusing on the parameters that should be considered. Furthermore, they addressed pulmonary function tests and wedge resection.   Joel also highlights recent JANS articles on European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer, a 10-year propensity-matched analysis on the impact of resident-led operating on outcomes in adult cardiac surgery, a systematic review and meta-analysis on no association between preprocedural fasting and witnessed pulmonary aspiration, and asking AI what a doctor looks like.  In addition, Joel explores robotic anterolateral approach for left secondary carinal tumor resection and reconstruction, neonatal Blalock-Taussig-Thomas shunt for double outlet right ventricle with RVOTO, and minimally invasive Bi-IMA OPCAB via left thoracotomy. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) European Respiratory Society and European Society of Thoracic Surgeons Clinical Practice Guideline on Fitness for Curative Intent Treatment of Lung Cancer  2.) Impact of Resident-Led Operating on Outcomes in Adult Cardiac Surgery: A 10-Year Propensity-Matched Analysis  3.) No Association Between Preprocedural Fasting and Witnessed Pulmonary Aspiration: A Systematic Review and Meta-Analysis  4.) What Does a Doctor Look Like? Asking AI  CTSNet Content Mentioned  1.) Robotic Anterolateral Approach for Left Secondary Carinal Tumor Resection and Reconstruction   2.) Neonatal Off-Pump Blalock-Taussig-Thomas Shunt for Double Outlet Right Ventricle With RVOTO   3.) Minimally Invasive Bi-IMA OPCAB Via Left Thoracotomy   Other Items Mentioned  1.) Instructional Video Competition   2.) Career Center   3.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

High-glycemic index foods push your insulin and IGF-1 into ranges linked to lung cancer, raising risk across multiple tumor types, including small cell and adenocarcinoma High-glycemic load diets, when built from fiber-rich whole fruits, vegetables, and grains, showed a lower lung cancer risk because they produced steadier blood sugar responses rather than sharp spikes Both smokers and nonsmokers experienced significantly higher lung cancer odds when eating high-GI diets, showing that carbohydrate quality influences risk regardless of smoking history Fast-absorbing carbs and ultraprocessed foods often combine high-GI starches with high linoleic acid seed oils, creating an inflammatory, insulin-resistant environment that supports abnormal cell growth Simple dietary shifts — such as reducing ultraprocessed foods, choosing slower-digesting carbs, repairing your gut before increasing fiber, and stabilizing meal timing — help you lower metabolic patterns linked to lung cancer

Jessica Donington, MD, and Christine Bestvina, MD, join host Erin Gillaspie, MD, to unpack key lung cancer advances from ESMO 2025, including adjuvant ALK inhibition (ALINA, ELEVATE), perioperative immunotherapy (KEYNOTE-671), and the expanding neoadjuvant space in borderline resectable disease.

Dr. Bryant Lin is a primary care physician, educator, and researcher at Stanford University. In 2018, he founded CARE – the Center for Asian Health Research and Education. In 2023, CARE began a focused research effort investigating lung cancer in non-smoking Asians. In 2024, Dr. Lin was diagnosed with Stage 4 lung cancer, having never smoked in his life. After his diagnosis, Dr. Lin sprung into action. He began receiving care from Dr. Heather Wakelee – a Stanford oncologist specializing in lung cancer. Dr Wakelee is the Deputy Director of the Stanford Cancer Institute, the Division Chief of Medical Oncology, and a leader in the International Association for the Study of Lung Cancer. In this episode, we are privileged to be joined by both Dr. Lin and his oncologist, Dr. Wakelee.Over the course of our conversation, Dr. Lin describes the experience of receiving and living with a diagnosis that has been life changing for both him and his family. He details his remarkable efforts to leverage his diagnosis for the good of patients and rising medical professionals  — and explains how spiritual practices have helped sustain him through this difficult time. Dr. Wakelee shares her approach to first visits with patients facing daunting cancer diagnoses, how she approaches grief, and the unique privilege and challenge of treating a colleague. Together, the doctor and his physician explore the value of hope in cancer, the dangers of false hope, and the importance of maximizing meaning in life — however much time is left. In this episode, you'll hear about: 2:50 - Dr. Lin's experience of being diagnosed with stage 4 lung cancer despite having never smoked14:20 - Dr. Wakelee's approach to first visits with newly diagnosed lung cancer patients25:35 - Dr. Lin's experience of shifting from the mindset of “doctor” to the mindset of “patient” 30:30 - How a doctor's messaging can affect the patient's outlook on their diagnosis43:00 - The common themes prevalent across religions and spiritual orientations that support patients in the navigation of serious illness50:24 - Advice to doctors for finding deeper meaning in medicineListen to Dr. Lin's first appearance on The Doctor's Art. If you enjoyed this episode, please subscribe, rate, and review our show, available for free on Spotify, Apple Podcasts, or wherever you get your podcasts. If you know of a doctor, patient, or anyone working in health care who would love to explore meaning in medicine with us on the show, feel free to leave a suggestion in the comments or send an email to info@thedoctorsart.com.Copyright The Doctor's Art Podcast 2026

This Biotech CEO Wants To Cure Lung Cancer – Maria Zanes President & CEO bioAffinity Technologies BIAF Ticker: BIAF Websitehttps://bioaffinitytech.com/Maria Zannes, Chief Executive Officer, President, and Director, bioAffinity Technologies, Inc. (NASDAQ: BIAF)BioSince founding bioAffinity Technologies in 2014, Ms. Zannes has built a team of award-winning scientists and executives who are advancing breakthrough diagnostics for lung cancer and other pulmonary diseases. The company's first commercial product, CyPath® Lung, is a noninvasive, accurate test for early-stage lung cancer that has proven to detect the disease as early as Stage 1A when it can be cured. Prior to bioAffinity Technologies, Ms. Zannes founded The Zannes Firm to provide strategic solutions for private industry in the medical, environmental and energy fields. Previously, she was President of the Energy Recovery Council, a national trade group and General Manager of ECOS Corporation, a subsidiary of Burlington Environmental. Earlier in her career, she was a legislative aide to Congressman Charles Wilson (D-TX) after having worked as a journalist for Voice of America and the Associated Press. She has been awarded Lifetime Achievement Awards by the American Society of Mechanical Engineers and the Earth Engineering Center Award from Columbia University. Ms. Zannes received her J.D. from the University of Puget Sound in Washington State and is licensed to practice law in New Mexico. bioAffinity Technologies, Inc. (Nasdaq: BIAF)Lung cancer remains the leading cause of cancer deaths worldwide with an estimated 1.8 million deaths annually. Diagnosing and treating early-stage lung cancer can significantly improve outcomes and increase patient survival. bioAffinity Technologies addresses the urgent need for noninvasive, accurate early-stage lung cancer diagnosis. The Company's lead product, CyPath® Lung, accurately detects early-stage lung cancer in high-risk patients as early as Stage 1A. Using CyPath® Lung as part of the diagnostic pathway can lead to earlier diagnosis, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs for the world's largest cancer killer. CyPath® Lung is sold as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a bioAffinity Technologies company, and reimbursed by Medicare, private payors and federal healthcare systems, including the VA. CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to detect cancer by analyzing the lung microenvironment. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in individuals with small indeterminate pulmonary nodules that often pose diagnostic challenges. The test provides actionable information for physicians to guide next steps in patient care. Physicians using CyPath® Lung for their high-risk patients have reported multiple case studies in which CyPath® Lung detected lung cancer at Stage 1A when standard imaging, risk calculator models and serum marker tests indicated the nodules were likely benign. Conversely, a negative CyPath® Lung result has spared many patients from unnecessary and sometimes risky invasive procedures, including biopsy.

Is the open thoracotomy becoming outdated as robotic surgery and advanced ablation techniques take center stage in lung cancer treatment? In the final discussion of the 2025 NSCLC Creator Weekend™ series, our virtual tumor board of interventional radiologists and pulmonologists from leading medical institutions discuss recent surgical and interventional advancements in the treatment of lung cancer. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS The conversation covers the contemporary role of PET scans, endobronchial ultrasound (EBUS), mediastinal staging, and the importance of perioperative systemic therapy. The doctors explore surgical and non-surgical methods for treating lung cancer, including lymph node dissection, criteria for resection, and the advantages of minimally invasive approaches such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgeries.A key focus of this episode is the decision-making process for treating multifocal lung cancers while preserving lung function, and the use of combined therapies like ablation and radiation. The episode concludes with a detailed case study illustrating the long-term management of a patient with multiple lung adenocarcinomas over several years, highlighting the multidisciplinary approach required in such complex scenarios. --- TIMESTAMPS 00:00 - Introduction10:07 - Patient Selection and Comorbid Conditions27:29 - Surgical Margins and Resection Strategies42:11 - Understanding Upstaging in Cancer Treatment53:27 - Technical and Clinical Resectability56:13 - Case Study: Managing Multifocal Lung Cancer01:11:41 - Long-Term Outcomes and Treatment Strategies --- RESOURCES CALGB 140503 Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2212083 JCOG0802 Trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02333-3/abstract

As Barry Manilow's recent lung cancer diagnosis reminded us, a persistent cough, chest pain, shortness of breath may be more than just annoying symptoms. In this episode, we explain the signs you shouldn't ignore, what testing and treatment may look like, and how hope is still part of the story.  https://bit.ly/4szFIiaIn this Episode:02:21 - Tips for Longevity from People in their 90's - Naomi Rose & Physical Fitness04:48 - Avocado Salsa: Marriage of Guacamole and Pico de Gallo05:47 - Barry Manilow's Lung Cancer Diagnosis07:05 - Review of Lung Anatomy, Lung Cancer Overview, Differences between NSCLC and SCLC 09:32 - What Increases Our Risk of Lung Cancer?10:35 - Lung Cancer Signs and Symptoms to Watch For12:49 - Treatment of Lung Cancer - Reasons for Hope15:46 - Cancer Survivorship: How to Lower Your Risk of Cancer Returning and Signs not to Ignore18:57 - Discussion with Charlie: Historical Smoking, Persistent Cough24:04 - 27 y.o. Alexa Bekkerus Self-Written Obituary - How She Found Peace Dying with Metastatic Breast Cancer29:21 - OutroSupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

- Understanding Precision Medicine: Overview & Value of Precision Medicine - How Precision Medicine is Different from Targeted Treatments? - Precision Medicine's Role in Informing Treatment Decisions: Predicting Response to Treatment - The Role of Precision Medicine in Deciding the Treatment for Lung Cancer, Leukemia, Colon Cancer & Prostate Cancer - Talking with Your Health Care Team About Precision Medicine & its Benefits - The Role of the Pathologist - OpenNotes – Asking Your Health Care Team & Pathologist to Help You Understand OpenNotes - How Precision Medicine Contributes to Treatment Options & Quality of Life - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology & Prepared List of Questions - Questions for Our Panel of Experts

- Understanding Precision Medicine: Overview & Value of Precision Medicine - How Precision Medicine is Different from Targeted Treatments? - Precision Medicine's Role in Informing Treatment Decisions: Predicting Response to Treatment - The Role of Precision Medicine in Deciding the Treatment for Lung Cancer, Leukemia, Colon Cancer & Prostate Cancer - Talking with Your Health Care Team About Precision Medicine & its Benefits - The Role of the Pathologist - OpenNotes – Asking Your Health Care Team & Pathologist to Help You Understand OpenNotes - How Precision Medicine Contributes to Treatment Options & Quality of Life - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology & Prepared List of Questions - Questions for Our Panel of Experts

- Understanding Precision Medicine: Overview & Value of Precision Medicine - How Precision Medicine is Different from Targeted Treatments? - Precision Medicine's Role in Informing Treatment Decisions: Predicting Response to Treatment - The Role of Precision Medicine in Deciding the Treatment for Lung Cancer, Leukemia, Colon Cancer & Prostate Cancer - Talking with Your Health Care Team About Precision Medicine & its Benefits - The Role of the Pathologist - OpenNotes – Asking Your Health Care Team & Pathologist to Help You Understand OpenNotes - How Precision Medicine Contributes to Treatment Options & Quality of Life - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology & Prepared List of Questions - Questions for Our Panel of Experts

- Understanding Precision Medicine: Overview & Value of Precision Medicine - How Precision Medicine is Different from Targeted Treatments? - Precision Medicine's Role in Informing Treatment Decisions: Predicting Response to Treatment - The Role of Precision Medicine in Deciding the Treatment for Lung Cancer, Leukemia, Colon Cancer & Prostate Cancer - Talking with Your Health Care Team About Precision Medicine & its Benefits - The Role of the Pathologist - OpenNotes – Asking Your Health Care Team & Pathologist to Help You Understand OpenNotes - How Precision Medicine Contributes to Treatment Options & Quality of Life - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology & Prepared List of Questions - Questions for Our Panel of Experts

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by CNN Medical Correspondent Meg Tirrell and WTOP reporter Neal Augenstein to discuss the role of the media in lung cancer awareness and perception. Traditional media, including television and radio, do much to shape the public perception of lung cancer and healthcare in general. Meg Tirrell and Neal Augenstein share their experiences reporting in the health sector, establishing trust with their audiences in the face of uncertainty, and distilling complex medical information to the general public.

Why might simultaneous ablation and biopsy be the new standard for high-probability lung cancer cases where surgery isn't an option? In the penultimate episode of the 2025 NSCLC Creator Weekend™ series, our multidisciplinary tumor board panel discusses the intricacies and decision-making processes surrounding biopsy and ablation procedures in thoracic oncology. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS Topics include the prioritization of treatment versus tissue acquisition, the nuances of bronchoscopic versus percutaneous biopsies, and the latest advancements in robotic and cryo-biopsy techniques. The experts also share their approaches to managing pneumothorax, the value of multidisciplinary collaboration, and case studies that highlight personalized patient care. Listeners gain valuable insights into the evolving landscape of thoracic oncology procedures and the importance of patient-centered decision-making. --- TIMESTAMPS 00:00 - Introduction04:12 - Cryobiopy vs. Non-Cryobiopsy08:43 - Biopsy and Ablation: Strategies and Considerations15:31 - Post-Therapy Imaging and Follow-Up25:18 - Treatment Options and Patient Decisions27:08 - Evaluating Ablation Techniques28:59 - Managing Lung Cancer Recurrence39:41 - Case Study: Young Male with Ground Glass Nodule43:15 - Concluding Thoughts

Drs. Yu and Herzberg discuss recent developments in HER2- and EGFR-targeted therapies for lung cancer, focusing on clinical trial results at ESMO 2025. Key highlights include promising response rates, toxicity profiles, and the potential for these targeted therapies to treat patients with specific genetic mutations, particularly those with CNS metastases.

Since the first immunotherapy agent for lung cancer was approved in 2015, this class of drugs has captured the imagination and the narrative for the treatment of driver negative lung cancer. Immunotherapy is now the standard of care for most patients with lung cancer in some form. And while not all patients benefit, those that do, have the chance for transformative benefit. In today's episode, we focus not on the benefit of immunotherapy, which can be massive, but on the toxicity of immunotherapy. Guest: Dr. Jarushka Naidoo, a consultant medical oncologist at Beaumont Hospital Dublin and a Professor in the Royal College of Surgeons in Ireland. She currently serves as national lung cancer lead for Cancer Trials Ireland and serves on several international guideline panels including ASCO and SITC

Drs. Herzberg and Yu continue their discussion on emerging clinical data presented at ESMO and WCLC 2025. They highlight recent advancements in HER2-targeted therapies for NSCLC and review new HER2-targeted therapies, international study results, and the promise of evolving targeted approaches for HER2-altered lung cancer.

Drs. Herzberg and Yu explore emerging clinical data from the 2025 meetings of the European Society For Medical Oncology (ESMO) and World Conference on Lung Cancer (WCLC), highlighting recent advancements in HER2-targeted therapies for NSCLC. Their discussion focuses on new drugs (eg, zongertinib and trastuzumab deruxtecan), their efficacy and safety profiles, and the potential for treating HER2 mutations and overexpression.

Program notes:0:40 Saturated fat and CVD1:40 When it was reduced in diet only helped in those with high risk2:40 Obesity, diabetes and metabolic syndrome also important3:30 Diagnostic follow up after lung CT4:30 Less intensive than recommended in non-Hispanic blacks5:31 Herpes antiviral and Alzheimer's6:30 Followed for five years7:30 80-90% of population exposed8:30 Change screening criteria for lung ca9:33 Population based study10:30 Calculating pack years11:20 Rolling out through national organizations12:17 End

In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).Presenters:John Heymach, MD, PhDChair and ProfessorDepartment of Thoracic/Head and Neck Medical OncologyRuth Legett Jones Distinguished ChairMD Anderson Cancer CenterHouston, TexasSolange Peters, MD, PhD Professor and Director of Medical OncologyDepartment of OncologyUniversity Hospital of LausanneLausanne, SwitzerlandContent based on an online CME program supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.Link to full program: https://bit.ly/3L1eksIGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The FDA has approved subcutaneous amivantamab. Join host Dr. Narjust Florez and guests, Dr. Natasha Leighl and Dr. Federico Cappuzzo, as they explore the science and convenience factor, as well as what this shift means for patients, clinicians, and oncology practice.

AP correspondent Haya Panjwani reports on a singer getting cancer surgery.

A new study out of India shows a bit of crossover between sarcoidosis and lung cancer.  In this episode of the FSR Sarc Fighter podcast, I'll take a look at the study and what it reveals — including a new drug, Metformin, previously used to treat Type 2 Diabetes, that may show promise based on the study's findings.  For what it's worth, I'll also share the terrors of surgery for my ruptured Achilles.       Show Notes:  Donate to FSR: https://stopsarcoidosis.rallybound.org/gratitude-and-giving-2025 FSR Biomarker Summit: https://www.stopsarcoidosis.org/fsr-convenes-global-leaders-for-landmark-clinic-alliance-meeting-and-sarcoidosis-biomarker-summit/ Sarcoidosis News Study from India: https://sarcoidosisnews.com/news/new-genetic-clues-connect-sarcoidosis-lung-cancer-risk More from FSR: https://www.stopsarcoidosis.org/fsr-receives-confirmation-from-the-department-of-labor-ensuring-patient-access-to-fmla-for-participation-in-clinical-trials/ MORE FROM JOHN: Cycling with Sarcoidosis http://carlinthecyclist.com/category/cycling-with-sarcoidosis/ Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser! If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.  https://stopsarcoidosis.rallybound.org/MarkSteier The Foundation for Sarcoidosis Research https://www.stopsarcoidosis.org/ Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR  https://stopsarcoidosis.rallybound.org/JohnCarlinVsSarcoidosis?fbclid=IwAR1g2ap1i1NCp6bQOYEFwOELdNEeclFmmLLcQQOQX_Awub1oe9bcEjK9P1E My story on Television https://www.stopsarcoidosis.org/news-anchor-sarcoidosis/ email me  carlinagency@gmail.com #sarcoidosis #sarcoidosisawareness #fmla #fmlaclarification #metformin  

 Lung cancer is commonly associated with smoking. However, among people diagnosed with lung cancer, the proportion who have never smoked has been increasing, and there are many reasons why a person who has never smoked may develop this disease. Lori Sakoda, PhD, MPH, ATSF, a research scientist and epidemiologist at Kaiser Permanente Northern California, explains what factors may come into play, what the ongoing research shows, and what knowledge gaps exist on this topic. Patti Tripathi hosts. 

In this special episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the IASLC | ASCO 2025 North America Conference on Lung Cancer. Dr. Igor Odintsov discusses updates in diagnostic pathology, including the integration of next-gen sequencing into the patient's journey. Dr. Byoung Chul Cho shares data from the phase 3 trial of gotistobart vs. docetaxel in patients with metastatic squamous cell lung cancer. Dr. Sulin Wu shares insights on the role of family history in lung cancer among women and low-exposure smokers.

In this episode of the Oncology Brothers podcast, we dived deep into the world of antibody drug conjugates (ADCs) in non-small cell lung cancer (NSCLC). We welcomed Dr. Jacob Sands from the Dana-Farber Cancer Institute to discuss the latest ADCs approved for NSCLC, including Trastuzumab deruxtecan (TDXd), Datopotamab deruxtecan (Dato-DXd), and Telisotuzumab Vedotin (Teliso-V). We explored the side effect profiles of these therapies, focusing on critical toxicities such as interstitial lung disease (ILD), mucositis, and peripheral neuropathy. Dr. Sands shared valuable clinical pearls on managing these adverse events, emphasized the importance of proactive monitoring and patient education. Key topics covered in this episode: • Overview of ADCs and their role in NSCLC treatment • TDXd: alopecia, ILD, fatigue, nausea/vomiting • Dato-DXd:  cytopenias, mucositis, dry eyes • Teliso-V: peripheral neuropathy, fatigue, peripheral edema • The evolving landscape of ADCs and future directions in lung cancer treatment Whether you're a healthcare professional or someone interested in oncology, this episode provides essential insights into the management of side effects associated with these innovative therapies. Tune in for practical advice and expert opinions that can enhance patient care in the community setting. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on practice-changing discussions in oncology! #ADC #NSCLC #TDXd #DatoDXD #TelisoV #ToxicityManagement #OncologyBrothers

Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen "Fred" Divers, including the following topics:  Introduction (0:00) Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32) Case: A woman in her mid 60s with ALK-mutant metastatic adenocarcinoma of the lung (PD-L1 TPS 70%) — Zanetta S Lamar, MD (17:59) Case: A woman in her mid 80s with EGFR exon 19-deleted adenocarcinoma of the lung with recurrence after 4 years of osimertinib — Jennifer Yannucci, MD (27:53) Case: A woman in her late 60s with HER2-mutant metastatic adenocarcinoma of the lung — Brian P Mulherin, MD (39:41) Case: A man in his early 70s with locally recurrent squamous cell carcinoma of the lung and a MET exon 14 skipping mutation — Sean Warsch, MD (46:39) Case: A woman in her early 70s with ROS1-mutant metastatic adenocarcinoma of the lung that responds to entrectinib and then to pembrolizumab/carboplatin/pemetrexed administered upon disease progression — Dr Yannucci (52:44) Nontargeted Therapy for NSCLC; Small Cell Lung Cancer — Dr Langer (58:16) Neoadjuvant, Perioperative and Adjuvant Anti-PD-1/PD-L1 Antibody-Based Approaches for Patients with Localized NSCLC — Dr Shields (1:14:14) Case: A man in his mid 60s with localized adenocarcinoma of the lung who receives neoadjuvant cisplatin/pemetrexed/pembrolizumab and achieves a pathologic complete response — Dr Mulherin (1:23:19) Case: A man in his early 60s with metastatic mixed adenosquamous NSCLC (PD-L1 TPS 50%) — Sunil Babu, MD (1:30:04) Case: A man in his late 50s diagnosed with extensive-stage small cell lung cancer who receives carboplatin/etoposide/durvalumab — Dr Warsch (1:34:07) CE information and select publications

 Lynette experienced severe symptoms before diagnosis including inability to walk short distances without collapsing, constant coughing that prevented speaking, and extreme fatigue that made basic activities impossible.Medical professionals initially prescribed antibiotics three times before ordering urgent X-rays and MRI scans, which led to immediate referral to a lung cancer specialist and hospitalization.Hospital procedures included draining 1.5 liters of fluid described as "porridge-like" from Lynette's lung cavity, followed by surgery to fuse the pleural lining, but the left lung had completely collapsed making the cancer inoperable.Doctors determined chemotherapy was not an option and sent Lynette home for palliative care with an estimated survival time of 12-18 months.Monica Hayes, Lynette's daughter and a registered nurse, developed a comprehensive treatment protocol inspired by her partner Craig Burrells who had survived cancer using similar methods.Treatment protocol consisted of THC oil administered rectally three times daily at seven-hour intervals, combined with a complete alkaline plant-based diet eliminating sugar, dairy, and meat.Monica initially administered the THC suppositories herself as a nurse before teaching her mother to self-administer, noting the confronting nature of the intimate medical care.Improvements became visible within the first two weeks including elimination of coughing, reduced shortness of breath, increased energy levels, and Lynette's ability to work in her garden.Additional treatments included ivermectin, fenbendazole antiparasitic medications, alkaline water, and CBD oil to counteract the psychoactive effects of THC while maintaining therapeutic benefits.After three months of treatment, scan results showed 80% cancer clearance, prompting Lynette to perform a celebratory tap dance for her oncologist.Lynette's oncologist was thrilled with the results and noted perfect blood work, though the medical team was not informed about the cannabis treatment due to legal concerns in Australia.Family members, initially skeptical, became amazed by the transformation and now call Monica a "miracle worker" after witnessing Lynette's complete symptom reversal.Lynette's next scan is scheduled for Friday to determine if further improvement has occurred, with hopes that her partially collapsed lung may have self-corrected.Both women advocate for cannabis legalization and encourage others facing terminal cancer diagnoses to consider THC oil treatment as a source of hope when conventional medicine offers only palliative care. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textLung cancer is often discovered too late, when treatments are expensive and survival rates are low. But what if routine chest x-rays could flag cancer early…long before symptoms appear? AI is transforming everyday imaging into a powerful early detection tool, reshaping screening economics and saving lives around the world. Prashant Warier, CEO and Founder of Qure.ai, joins CareTalk to discuss how AI enables earlier diagnosis, why chest x-rays are an untapped opportunity for detection, and what it takes to integrate AI into national health systems at scale.

Dr. Trudy G. Oliver is a Professor in the Department of Pharmacology & Cancer Biology as well as a Duke Science and Technology Scholar at Duke University. Trudy's research focuses on small cell lung cancer, a disease known for its remarkable ability to "shape-shift" or undergo cellular plasticity. This adaptability allows cancer cells to change types and develop different therapeutic vulnerabilities (or invulnerabilities), making treatment especially challenging and preventing the development of a one-size-fits-all approach. When she's not in the lab, Trudy unwinds with walks, jogs, music, and true-crime podcasts. She also enjoys spending quality time with friends, family, and her two energetic orange kittens named Basal and Tuft after her favorite lung cell types. She received her Bachelor's degree in chemistry from Oklahoma Baptist University, and her PhD in cancer biology from Duke University. Afterwards, she conducted postdoctoral research at the University of North Carolina, Chapel Hill, and subsequently at MIT. Trudy served on the faculty at the University of Utah for more than a decade before joining the faculty at Duke University where she is today. She has received numerous awards and honors for her work, including the Heine H. Hansen Lectureship Award for Small Cell Lung Cancer from the IASLC World Lung Conference, the William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation, the Lung Cancer Discovery Award from the American Lung Association, the American Cancer Society Research Scholar Award, the Damon Runyon-Rachleff Innovation Award, and the Jimmy V Scholar Award from the V Foundation for Cancer Research. In this interview, Trudy shares more about her life and science.

How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung cancer patient's treatment plan? In this episode of the 2025 NSCLC Creator Weekend™ series, our tumor board discusses the complexities of lung cancer treatment, including new systemic therapies, lung cancer staging, and the role of molecular diagnostics and liquid biopsies. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS The panel, featuring specialists from various institutions, discusses the specifics of sequencing therapies, the impact of targeted and immunotherapies, and the nuances of treating different patient profiles, including non-smokers and those with specific genetic mutations. The conversation also touches on the integration of new staging systems, the benefits of multidisciplinary clinics, and the ongoing evolution of cancer treatment trials. The discussion aims to provide clarity on the latest advancements and future directions in managing lung cancer, emphasizing the importance of tailored treatment plans and the potential of emerging technologies. --- TIMESTAMPS 00:00 - Introduction05:16 - Molecular Diagnostics and Liquid Biopsy21:43 - Targeted Therapy Options27:29 - Managing Toxicities and Treatment Strategies33:13 - Challenges with Immunotherapy in Special Cases34:07 - Lung Transplantation in Cancer Patients48:38 - Multidisciplinary Clinics and Collaboration01:06:29 - Future Directions --- RESOURCES ADAURA Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2027071 Gomez NSCLChttps://pmc.ncbi.nlm.nih.gov/articles/PMC5143183/

Lung cancer is the most prevalent cancer in the Rochester and Finger Lakes region. That's according to experts at the University of Rochester Medical Center. They say screening has been underutilized due to the stigma of the disease. This hour, we discuss their efforts to change that. They also explain what they call a "soup to nuts" approach to addressing the disease, which includes prevention and screening, early diagnosis, and advanced treatment options. Our guests: Racquel Stephen, health, equity and community reporter and producer for WXXI News Charles Kamen, Ph.D., M.P.H., associate director of community outreach and engagement at Wilmot Cancer Institute at the University of Rochester Medical Center M. Patricia Rivera, M.D., C. Jane Davis & C. Robert Davis Distinguished Professor in Pulmonary Medicine and chief of the Pulmonary and Critical Care Medicine Division at University of Rochester Medical Center Joyce Lucas, patient ---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.